

Name of Journal: *World Journal of Meta-Analysis*

Manuscript NO: 61346

Manuscript Type: MINIREVIEWS

NUSINERSEN, NEWER DRUG FOR SPINAL MUSCULAR ATROPHY

"NUSINERSEN, AN EXON 7 INCLUSION DRUG FOR SPINAL MUSCULAR ATROPHY: A MINIREVIEW"

Abstract

Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease with incidence of 1 in 5000 to 10,000 Live births and is produced by homozygous deletion of exons 7 and 8 in the SMN1 gene. The SMN1 and SMN2 genes encode the SMN protein, a crucial protein for the preservation of motor neurons. Newer drug, Nusinersen, from early infancy has shown improvement in clinical outcomes of SMA patients.

Match Overview

1	Internet 57 words crawled on 28-Apr-2020 www.nice.org.uk	2%
2	Internet 47 words crawled on 12-May-2019 www.amyotrophie-spinale.info	2%
3	Internet 35 words crawled on 02-Feb-2021 www.indianpediatrics.net	1%
4	Internet 30 words crawled on 27-Dec-2020 www.scilit.net	1%
5	Internet 26 words crawled on 08-May-2021 www.mdpi.com	1%
6	Internet 25 words crawled on 13-Jan-2020 journals.sagepub.com	1%
7	Internet 24 words crawled on 23-Apr-2021 pubmed.ncbi.nlm.nih.gov	1%
8	Internet 19 words crawled on 14-Jan-2018	1%

Nusinersen, an exon 7 inclusion drug for spinal muscular atrophy: A



ALL

IMAGES

VIDEOS

23,300 Results

Any time ▾

Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy

<https://pubmed.ncbi.nlm.nih.gov/32233169>

Abstract. The reduction of survival motor neuron (SMN) protein causes **spinal muscular atrophy** (SMA), an autosomal recessive neuromuscular disease. Nusinersen is an **antisense oligonucleotide**, approved by the FDA, which specifically binds to the repressor within SMN2 exon 7 to enhance exon 7 inclusion and augment production of functional SMN protein. Nusinersen is the first new oligonucleotide-based drug ...

Cited by: 9

Author: Qing Li

Publish Year: 2020

Nusinersen, an antisense oligonucleotide drug for spinal ...

<https://www.nature.com/articles/nn.4508>

Feb 13, 2017 · **Nusinersen (Spinraza)** is a recently approved **drug** for treating **spinal muscular atrophy**. Approval of **nusinersen** may signal new opportunities for using **antisense oligonucleotides** ...

Cited by: 170

Author: David R Corey

Publish Year: 2017

PEOPLE ALSO ASK

How is nusinersen used to treat spinal muscular atrophy? ▾

How is nusinersen used in the treatment of SMA? ▾

How are antisense oligonucleotides used to treat spinal muscular atrophy? ▾

23,300 Results Any time

Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy

https://pubmed.ncbi.nlm.nih.gov/32233169

Abstract. The reduction of survival motor neuron (SMN) protein causes **spinal muscular atrophy** (SMA), an autosomal recessive neuromuscular disease. Nusinersen is an **antisense oligonucleotide**, approved ...

Cited by: 9 Author: Qing Li Publish Year: 2020

Nusinersen, an antisense oligonucleotide drug for spinal ...

https://www.nature.com/articles/nn.4508

Feb 13, 2017 · **Nusinersen (Spinraza)** is a recently approved **drug** for treating **spinal muscular atrophy**. Approval of **nusinersen** may signal new opportunities for using **antisense oligonucleotides** ...

Cited by: 170 Author: David R Corey Publish Year: 2017

People also ask

- How is nusinersen used to treat spinal muscular atrophy?
- How is nusinersen used in the treatment of SMA?
- How are antisense oligonucleotides used to treat spinal muscular atrophy?
- Where does nusinersen pair with SMN2 mRNA?

Feedback

Nusinersen in the Treatment of Spinal Muscular Atrophy


https://pubmed.ncbi.nlm.nih.gov/30171535

Nusinersen in the Treatment of **Spinal Muscular Atrophy**. **Spinal muscular atrophy** (SMA) is one of the most common genetic causes of infantile death arising due to mutations in the SMN1 gene and the...

Cited by: 12 Author: Kara Goodkey, Tejal Aslesh, Rika Maruyam... Publish Year: 2018

Nusinersen for spinal muscular atrophy | Neurology

Nusinersen



Nusinersen, marketed as Spinraza, is a medication used in treating spinal muscular atrophy, a rare neuromuscular disorder. In December 2016, it became the first approved drug used in treating this disorder.



Data from: Wikipedia Suggest an edit